Welcome to our dedicated page for ARCELLX SEC filings (Ticker: ACLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcellx, Inc. filings document the company's completed acquisition by Gilead Sciences and the related changes to its public-company status. The Form 8-K record covers completion of the transaction, material-event disclosure, capital-structure matters, and prior operating and financial results.
Arcellx's later regulatory record includes a Form 25 for removal of its common stock from Nasdaq listing and registration, followed by a Form 15 terminating or suspending Exchange Act reporting obligations for the class of securities. These filings establish the company's transition from a Nasdaq-listed biotechnology issuer to a wholly owned subsidiary with one holder of record.
Perceptive Advisors and affiliated parties reported beneficial ownership of 2,478,000 shares of Arcellx, Inc. (ACLX), representing 4.5% of the outstanding common stock based on 55,458,912 shares outstanding as of August 1, 2025. The filing shows the Master Fund directly holds the 2,478,000 shares, with Perceptive Advisors serving as investment manager and Joseph Edelman identified as managing member. All three reporting persons report shared voting and dispositive power over those shares and report no sole voting or dispositive power. The Schedule 13G/A is filed under the passive investor framework and contains standard certifications and signatures by Joseph Edelman.